This company has been marked as potentially delisted and may not be actively trading. Innovate Biopharmaceuticals (INNT) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesTrendsBuy This Stock INNT vs. VRPX, TRVN, ARDS, STAB, EVLO, AMPE, CMRA, PXMD, EFTR, and HSTOShould you be buying Innovate Biopharmaceuticals stock or one of its competitors? The main competitors of Innovate Biopharmaceuticals include Virpax Pharmaceuticals (VRPX), Trevena (TRVN), Aridis Pharmaceuticals (ARDS), Statera Biopharma (STAB), Evelo Biosciences (EVLO), Ampio Pharmaceuticals (AMPE), Comera Life Sciences (CMRA), PaxMedica (PXMD), eFFECTOR Therapeutics (EFTR), and Histogen (HSTO). These companies are all part of the "medical" sector. Innovate Biopharmaceuticals vs. Its Competitors Virpax Pharmaceuticals Trevena Aridis Pharmaceuticals Statera Biopharma Evelo Biosciences Ampio Pharmaceuticals Comera Life Sciences PaxMedica eFFECTOR Therapeutics Histogen Innovate Biopharmaceuticals (NASDAQ:INNT) and Virpax Pharmaceuticals (NASDAQ:VRPX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and profitability. Which has stronger valuation & earnings, INNT or VRPX? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInnovate BiopharmaceuticalsN/AN/A-$27.05MN/AN/AVirpax PharmaceuticalsN/AN/A-$15.19MN/AN/A Does the media favor INNT or VRPX? In the previous week, Innovate Biopharmaceuticals' average media sentiment score of 0.00 equaled Virpax Pharmaceuticals'average media sentiment score. Company Overall Sentiment Innovate Biopharmaceuticals Neutral Virpax Pharmaceuticals Neutral Do institutionals and insiders believe in INNT or VRPX? 5.9% of Innovate Biopharmaceuticals shares are held by institutional investors. Comparatively, 32.2% of Virpax Pharmaceuticals shares are held by institutional investors. 7.9% of Innovate Biopharmaceuticals shares are held by company insiders. Comparatively, 3.7% of Virpax Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Is INNT or VRPX more profitable? Innovate Biopharmaceuticals' return on equity of 0.00% beat Virpax Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Innovate BiopharmaceuticalsN/A N/A -234.42% Virpax Pharmaceuticals N/A -1,554.34%-338.29% Which has more risk and volatility, INNT or VRPX? Innovate Biopharmaceuticals has a beta of -0.39, suggesting that its share price is 139% less volatile than the S&P 500. Comparatively, Virpax Pharmaceuticals has a beta of 1.96, suggesting that its share price is 96% more volatile than the S&P 500. SummaryInnovate Biopharmaceuticals and Virpax Pharmaceuticals tied by winning 3 of the 6 factors compared between the two stocks. Get Innovate Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for INNT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INNT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip Chart INNT vs. The Competition Export to ExcelMetricInnovate BiopharmaceuticalsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$8K$787.62M$6.05B$10.30BDividend YieldN/A4.84%5.73%4.82%P/E Ratio0.001.2885.1927.10Price / SalesN/A29.85597.83133.24Price / CashN/A17.6425.7730.18Price / BookN/A7.5412.626.69Net Income-$27.05M-$7.59M$3.32B$276.55M Innovate Biopharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INNTInnovate BiopharmaceuticalsN/AN/AN/AN/A$8KN/A0.008VRPXVirpax Pharmaceuticals0.0509 of 5 stars$0.02+90.9%N/A-99.8%$26KN/A0.007Gap UpTRVNTrevena1.6174 of 5 stars$0.01flat$5.00+41,566.7%-99.4%$12K$443K0.0040ARDSAridis PharmaceuticalsN/A$0.00flatN/AN/A$11KN/A0.0030STABStatera BiopharmaN/A$0.00flatN/A-50.0%$5KN/A0.0020Gap DownEVLOEvelo BiosciencesN/A$0.00-60.0%N/AN/A$4KN/A0.00120AMPEAmpio PharmaceuticalsN/A$0.00flatN/A+22.7%$3KN/A0.0020CMRAComera Life SciencesN/AN/AN/AN/A$3K$1.00M0.002PXMDPaxMedicaN/AN/AN/A-99.9%$2KN/A0.002EFTReFFECTOR Therapeutics0.0546 of 5 stars$0.00flatN/A-99.2%$1KN/A0.0010HSTOHistogenN/A$0.00flatN/A-99.9%$1K$19K0.0020 Related Companies and Tools Related Companies VRPX Competitors TRVN Competitors ARDS Competitors STAB Competitors EVLO Competitors AMPE Competitors CMRA Competitors PXMD Competitors EFTR Competitors HSTO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INNT) was last updated on 10/14/2025 by MarketBeat.com Staff From Our PartnersREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | SponsoredWhat if your job didn’t matter — and neither did China’s chip ban?If you’ve been watching the headlines lately…You’ve seen how Nvidia and AMD just got the green light to resume...Timothy Sykes | SponsoredAI's Next Magnificent SevenThe original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredThe Army Just Got a New Drone SupplierA cutting-edge drone developer just secured a U.S. Army deal to supply its Flex FPV Modular Drones and build a...The Tomorrow Investor | SponsoredNvidia CEO shares biggest regret?Earlier this year I predicted that the only reason Elon was in Washington was to push an AI-first agenda. Sinc...Altimetry | SponsoredBlackRock’s Shocking Crypto MoveBlackRock, Fidelity, and JPMorgan have quietly shifted billions out of Bitcoin and into a single emerging cryp...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Innovate Biopharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Innovate Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
